YURAK ISHEMIK KASALLIGIDA INTEGRIN GENLAR POLIMORFIZMI VA ERUVCHAN FIBRIN-MONOMER KOMPLEKSINING GIPERKOAGULYATSION SINDROM RIVOJLANISHIDAGI ROLI

Dildora Nasretdenova

Authors

Dildora Nasretdenova Urganch davlat tibbiyot instituti «Ichki kasalliklar va dermatovenerologiya» kafedrasi Tibbiyot fanlari bo'yicha falsafa doktori (PhD), katta o'qituvchi Author

Keywords:

yurak ishemik kasalligi, integrin genlar, ITGB3, ITGA2, polimorfizm

Abstract

Ushbu maqolada yurak ishemik kasalligi (YIK) bilan og'riyotgan bemorlarda ikkita patogenetik muhim mexanizm — integrin genlar polimorfizmi va eruvchan fibrin-monomer kompleksi (EFMK) — birgalikda tahlil qilinadi. Maqsad: YIK bemorlarida ITGB3 (rs918, Leu59Pro T>C) va ITGA2 (rs1126643, 807C>T) genlarining alel chastotasini aniqlash, shuningdek EFMK ko'rsatkichining diagnostik va patogenetik ahamiyatini baholash. Material va usullar: Genotiplash 118 nafar YIK bemorida PCR-RFLP usulida amalga oshirildi; 32 nafar bemorning venoz qonida EFMK darajasi o'lchandi. Natijalar: ITGB3 rs918 mutant C alleli bemorlarning 45,8% ida, ITGA2 rs1126643 mutant T alleli 41,7% ida aniqlandi. EFMK o'rtacha darajasi 4,56 ± 0,36 mg/dl ni tashkil etdi; bemorlarning 18,75% ida me'yordan oshgan EFMK qayd etildi. Xulosa: Integrin polimorfizmlari trombotsit faolligini kuchaytirsa, EFMK oshishi koagulyatsion kaskad faollashuvini aks ettiradi — ushbu ikkala mexanizm sinergistik tarzda giperkoagulyatsion sindrom shakllanishiga zamin yaratadi. Ikkala biomarker YIK bemorlarida trombotik xavfni individuallashtirishda farmakogenetik va diagnostik ahamiyatga ega

Downloads

Download data is not yet available.

References

1. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2(1):15–28.

2. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin αIIbβ3) odyssey. Blood. 2008;112(8):3011–3025.

3. Moshfegh K, et al. Two adjacent genetic polymorphisms within the receptor-binding domain of the β3-integrin gene are associated with different risks of thrombosis. Thromb Haemost. 1999;82(3):1211–1215.

4. Kunicki TJ, et al. The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol. 2001;21(6):1132–1138.

5. Kadirova N.A., Nasretdenova D.O. Izuchenie chastoty polimorfizmov genov FBG i PAI-1 pri arterialnoy gipertenzii // Sbornik tezisov XXII Vserossiyskogo kongressa «Arterialnaya gipertoniya 2026». — 2026. — S. 16.

6. Barkazan Z.S., Momot A.P. Diagnostika i kontroliruemaya terapiya narusheniy gemostaza. — Moskva: N'yudiamed, 2008. — 292 s.

7. Weng Z, et al. Platelet function genetic polymorphisms and cardiovascular disease risk. J Thromb Thrombolysis. 2015;39(3):265–274.

8. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26(7):2181–2188